Phathom Pharmaceuticals, Inc.
PHAT
$10.58
-$0.21-1.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 33.82% | 19.12% | -11.12% | -40.21% | -65.84% |
| Total Depreciation and Amortization | -20.38% | -11.31% | 2.23% | 17.88% | 38.26% |
| Total Amortization of Deferred Charges | 37.50% | 33.11% | 27.19% | 30.13% | 16.78% |
| Total Other Non-Cash Items | -20.87% | -25.01% | -15.46% | -5.39% | 6.20% |
| Change in Net Operating Assets | 19.10% | -355.75% | -139.97% | -297.39% | -12.12% |
| Cash from Operations | 37.48% | 8.85% | -27.49% | -69.34% | -93.90% |
| Capital Expenditure | -69.63% | 75.70% | 89.07% | 92.26% | 91.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -69.63% | 75.70% | 89.07% | 92.26% | 91.74% |
| Total Debt Issued | -- | -89.97% | -89.97% | -77.69% | -71.98% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.67% | -98.63% | 362,938.24% | -12.82% | -20.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.16% | -92.99% | -39.93% | -52.43% | -50.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -98.85% | -264.89% | -526.14% | -156.36% | -136.84% |